MannKind (MNKD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.01
- Estimate
- $0.02
- Surprise
- -157.1%
- Revenue (period 2026-06-30)
- $109.4M
- Score at report (before → after)
- 5.6 → 5.8/10
Revenue source: xbrl.
How the report landed
MannKind (MNKD) reported a wider loss than forecast — diluted EPS of -$0.01 against the $0.02 estimate (a 157.1% shortfall). TrendMatrix's engine moved from Buy (Wait) (5.6/10) to Sell at 5.8/10 after the report — the engine's score rose despite the miss.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MNKD Sell at 6.3/10.
1 of the last 4 quarters beat the estimate; this quarter's -157.1% surprise compares with a -227.7% four-quarter average. Next scheduled report: 2026-11-04.
What supports the rating
- Attractive valuation
- Strong growth profile
What argues against it
- Concentration risk — Supplier: Amphastar (sole insulin supplier for Afrezza)
- Consecutive earnings misses (3)
- Negative news sentiment (-0.67)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.12
- Price target
- $6.93
- Stop
- $3.86
- Upside to target
- +68.2%
- Reward-to-risk
- 5.3:1
Model outputs from TrendMatrix’s engine as of 2026-08-24 — shown for context, not personalized investment advice.
MNKD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.33B
- P/E (fwd)
- 32.5
- 52-week range
- $2.23–$6.51
- Off 52-week high
- 36.7%
- RSI (14)
- 59
- Volume vs avg
- 0.68×
- Score today
- 6.3/10